Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.
News|Articles|March 28, 2025 (Updated: March 28, 2025)
5 pediatric FDA decisions to watch for in Q2 2025
A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments.
Advertisement
Advertisement
As we transition into the second quarter of 2025, pediatric health care providers are keeping a close eye on a slate of anticipated FDA decisions that could reshape the treatment landscape for children and adolescents.
Related to this article
With California WNV activity at a 5-year high, CHLA outlines age-based repellent and bite-prevention guidance for children.
Johanna Chang, MD, offers guidance on vaccination, infection prophylaxis, and clinical warning signs in children receiving biologic therapies.
A Contemporary Pediatrics Peer Exchange panel reviews RSV risk, testing, maternal vaccination, and long-acting monoclonal antibodies, and where infants still slip through the cracks.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
Diana F. Clarke, PharmD, explains how IMPAACT 2023 supported dolutegravir from birth, plus dosing tips and open questions for preterm infants.
A recap of the top pediatric clinical trial results and pipeline data readouts during October 2026.
A recap of the top FDA approvals, regulatory decisions, and pipeline updates affecting pediatric care during October 2026.
Advertisement
Advertisement